Description: Immunome Inc., a biotechnology company, discovers, develops, and commercializes highly targeted and native human cancer antibodies against universal cancer antigens. Its RealMAb technology enables the discovery of novel antigens and the cognate native human antibodies that target antigens; and ScreenMab multiplex functional screening technology identifies monoclonal antibodies that have exquisite for tumor neoantigens. The company was founded in 2006 and is based in Exton, Pennsylvania.
Home Page: immunome.com
IMNM Technical Analysis
665 Stockton Drive
Exton,
PA
19341
United States
Phone:
610 321 3700
Officers
| Name | Title |
|---|---|
| Dr. Purnanand Duddu Sarma Ph.D. | Pres, CEO & Director |
| Ms. Corleen M. Roche | Chief Financial Officer |
| Dr. Dennis H. Giesing Ph.D. | Chief Devel. Officer |
| Dr. Scott K. Dessain M.D., Ph.D. | Co-founder & Chairman of the Scientific Advisory Board |
| Dr. Matthew K. Robinson Ph.D. | Chief Technology Officer |
| Dr. Michael J. Morin Ph.D. | Chief Scientist |
| Ms. Sandra G. Stoneman Esq. | Chief Legal Officer, Gen. Counsel & Corp. Sec. |
| Mr. Robert Lapetina | VP of Fin. & Corp. Controller |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.9966 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-10-02 |
| Fiscal Year End: | December |
| Full Time Employees: | 39 |